Abstract:BACKGROUND Anterior gradient 2 (AGR2) is associated with metastatic progression in prostate cancer cells as well as other normal and malignant tissues. We investigated AGR2 expression in patients with metastatic prostate cancer. METHODS Blood was collected from 44 patients with metastatic prostate cancer separated as: castration sensitive prostate cancer (CSPC, n?=?5); castration resistant prostate cancer (CRPC, n?=?36); and neuroendocrine-predominate CRPC defined by PSA?=?1?ng/ml in the presence of wide-spread metastatic disease (NE-CRPC, n?=?3). AGR2 mRNA levels were measured with RT-PCR in circulating tumor cell (CTC)-enriched peripheral blood. Plasma AGR2 levels were determined via ELISA assay. AGR2 expression was modulated in prostate cancer cell lines using plasmid and viral vectors. RESULTS AGR2 mRNA levels are elevated in CTCs and strongly correlated with CTC enumeration. Plasma AGR2 levels are elevated in all sub-groups. AGR2 levels vary independently to PSA and change in some patients in response to androgen-directed and other therapies. Plasma AGR2 levels are highest in the NE-CRPC sub-group. A correlation between AGR2, chromagranin A (CGA), and neuron-specific enolase (NSE) expression is demonstrated in prostate cancer cell lines. CONCLUSIONS We conclude that AGR2 expression is elevated at the mRNA and protein level in patients with metastatic prostate cancer. In particular, we find that AGR2 expression is associated features consistent with neuroendocrine, or anaplastic, prostate cancer, exemplified by an aggressive clinical phenotype without elevation in circulating PSA levels. Further studies are warranted to explore the mechanistic and prognostic implications of AGR2 expression in this patient population. Prostate 73: 306315, 2013. (c) 2012 Wiley Periodicals, Inc.

The expression of AGR2 in pituitary adenomas and its association with tumor invasiveness

Expression of AGR2 in pituitary adenomas and its association with tumor aggressiveness

Potential biomarkers and lncRNA-mRNA regulatory networks in invasive growth hormone-secreting pituitary adenomas

AGR2 is associated with gastric cancer progression and poor survival.

Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.

Prevalence and Significance of AGR2 Expression in Human Cancer

Expression of Pituitary Tumor Transforming Gene, Basic Fibroblast Growth Factor and Proliferating Cell Nuclear Antigen in Human Pituitary Adenomas: Correlation with Invasiveness

Association of Expression of Leucine-Rich Repeats and Immunoglobulin-Like Domains 2 Gene with Invasiveness of Pituitary Adenoma

The prognostic value of AGR2 expression in solid tumours: a systematic review and meta-analysis

AGR2 Promotes the Proliferation, Migration and Regulates Epithelial-Mesenchymal Transition in Salivary Adenoid Cystic Carcinoma

Anterior Gradient Protein 2 Expression in High Grade Head and Neck Squamous Cell Carcinoma Correlated with Cancer Stem Cell and Epithelial Mesenchymal Transition

AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer

Expression of Pituitary Tumor Transforming Gene in Pituitary Macroadenomas and Its Relationships with Tumor Invasiveness

Expressions of Gal-3 and Bcl-2 and their relationship with the invasiveness in pituitary adenomas

Research Advance of Pro-Metastatic Protein Anterior Gradient-2

Identification of Gene Co-Expression Modules and Hub Genes Associated with the Invasiveness of Pituitary Adenoma

Expression of Pituitary Tumor Transforming Gene PTTG in Pituitary Macroadenomas

Expression of Pituitary Tumor Transforming Gene (pttg),bfgf and Invasiveness of Pituitary Adenoma

Expression of EphA2 and E-cadherin in invasive pituitary adenoma and it's clinical significance

The Correlativity of PTEN,Survivin and PTTG with the Invasiveness of Pituitary Adenoma